The CEACAM1 expression is decreased in the liver of severely obese patients with or without diabetes by Lee, Wonae
RESEARCH Open Access
The CEACAM1 expression is decreased in the
liver of severely obese patients with or without
diabetes
Wonae Lee
Abstract
Background: Type 2 diabetes is mainly caused by insulin resistance. The carcinoembryonic antigen-related cell
adhesion molecule 1 (CEACAM1) is an important candidate for causing insulin resistance.
Methods: The CEACAM1 expression was evaluated immunohistochemically in the liver tissues of 99 severely obese
or non-obese subjects with or without diabetes. The CEACAM1 expression was classified into two categories: a
normal expression or a decreased expression.
Results: The CEACAM1 expression was markedly decreased in the hepatocytes with macrovesicular steatosis.
A decreased CEACAM1 expression was noted in 29 (29%)o f9 9c a s e s .T h ei n c i d e n c eo fad e c r e a s e dC E A C A M 1
expression was significantly higher in high grade fatty liver as well as severe obesity with or without diabetes
(p < 0.05). The incidence of a decreased CEACAM1 expression was not different between the diabetic and
non-diabetic groups.
Conclusions: This data supports that a decreased CEACAM1 expression is related to obesity and a fatty liver.
Background
Diabetes is one of the most problematic diseases in the
w o r l d ,a n di ti sag r o u po fm e t a b o l i cd i s e a s es h a r i n g
hyperglycemia. Approximately 90-95% of diabetic
patients have type 2 diabetes in which insulin resistance
predates the development of hyperglycemia and then b-
cell dysfunction ensues [1,2]. The molecular cause of
insulin resistance is very complicated and this has not
yet been clarified. The recent data from articles suggests
that carcinoembryonic antigen-related cell adhesion
molecule 1 (CEACAM1) is an important candidate
molecules that may cause insulin resistance.
CEACAM1 protein is also known as CD66a protein,
and the CEACAM1 gene is a human gene that encodes
a member of the carcinoembryonic antigen gene family
[3,4]. CEACAM1 protein has been implicated in intra-
cellular adhesion, intracellular signaling that governs the
growth and differentiation of normal and cancerous
cells, and the modulation of immune responses [3,5-8].
CEACAM1 protein is a cell-cell adhesion molecule
detected in the pericannalicular region of hepatocytes
[9]. CEACAM1 is a liver-specific transmembrane gyco-
protein and it is also a substrate of insulin receptor in
liver [10,11]. CEACAM1 is phosphorylated in response
to insulin in hepatocytes and it plays a role in insulin
clearance by increasing receptor-mediated endocytosis
[12,13]. Inactivation of CEACAM1 impairs insulin clear-
ance and causes hyperinsulinemia, insulin resistance,
dyslipidemia and visceral adiposity in transgenic mice
[14]. Thus, there is a strong association between severe
visceral obesity, insulin resistance and a reduced hepatic
CEACAM1 level [14,15].
The studies that have focused on CEACAM1 related
to insulin resistance have mainly been done on experi-
mental animal models and using molecular biologic
methods [14,15]. Immunohistochemical studies for
determining the CEACAM1 expression have rarely been
done in human non-neoplastic liver tissue. The aim of
this study is to evaluate the expression of CEACAM1 in
the human liver tissue of diabetics and non-diabetics
who are with or without severe obesity. Correspondence: walee@dankook.ac.kr
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Subjects and samples
A total of 99 cases of liver tissue obtained from diabetic
or non-diabetic subjects with or without severe obesity
were selected for this study. The age of subjects ranged
from 32 to 81 years old (mean: 58.0). Forty cases were
obtained from severely obese patients whose body mass
index (BMI) ranged from 34 to 67 (mean: 49). They
underwent bariatric surgery at the Wakefield hospital in
New Zealand. Liver wedge biopsies were done during the
gastric bypass surgeries. The average biopsy size was
about 2 mm at the greatest dimension. Twenty of 40
severely obese patients had diabetes and 20 of them were
non-diabetics. Eight of the 20 severely obese non-
diabetics had an abnormal oral glucose tolerance test and
they had not yet developed diabetes. Fifty-nine cases
were not severely obese patients who were selected from
the files of Dankook University Hospital. These patients
underwent hepatectomy due to primary or metastatic
liver tumor or hepatolithiasis. Among the 59 non-obese
patients, 29 patients had diabetes and 30 patients were
non-diabetics. Using the paraffin blocks of the hepatect-
omy specimens, a tissue microarray with 2 mm-sized
cores was made. Histologically, all cases were examined
for the degree of fatty liver which was graded as low
g r a d e=f a t t yc h a n g ei nm o r et h a n5 %a n dl e s st h a n3 3 %
of hepatocytes and high grade = fatty change in more
than 33% of hepatocytes. The severely obese cases were
examined for nonalcoholic steatohepatitis (NASH)
according to standarized criteria recommended [16]. The
liver of non-obese group was not examined for NASH
because this group was heterogeneous and inadequate to
be assessed for NASH.
Immunohistochemistry
Immunohistochemical staining was done using the for-
malin-fixed paraffin-embedded sections. The sections
were deparaffinized with xylene and rehydrated with
ethanol. Microwave antigen retrieval was performed
with 10 mM sodium citrate buffer. The sections were
incubated for 20 minutes in 0.3% H2O2 to block the
endogenous peroxidase activity. The sections were then
incubated with primary antibody for 60 minutes at
room temperature. The primary antibody used was anti-
CEACAM-1 mouse monoclonal antibody (1:50, 29H2,
Abcam, Cambridge, UK). After washing, the sections
were incubated with ImmPRESS™ universal reagent
(Abcam) for 40 minutes. Next the sections were incu-
bated with 3, 3’-diaminobenzidine substrate (Zymed,
South San Francisco, CA) for 5 min, washed, counter-
stained with Mayer’s hematoxylin, rinsed and mounted.
The CEACAM1 expression was classified into two
categories according to the previous report: a normal
expression when positive membranous staining was
noted throughout the examined liver specimen or a
decreased expression when distinct areas of negative
staining were noted within the examined liver specimen
[16].
Statistical analysis
Statistical analysis was performed by using the chi-
square test. The results were considered to be statisti-
cally significant when the p values were less than 0.05.
All statistical analyses were conducted using the SPSS
12.0 statistical software program (SPSS, Chicago, IL,
USA).
Results
The relationship of fatty liver and high grade fatty liver
with diabetics and severe obesity was summarized in
T a b l e1 .S o m ed e g r e eo ff a t t yl i v e rw a sn o t e di n6 3
(64%) of the total of 99 subjects: in 37 (93%) of 40
severely obese subjects and in 26 (44%) of 59 non-obese
subjects. The incidence of fatty liver was significantly
higher in the severely obese group than the non-obese
group (p < 0.05). High grade fatty liver was noted in 35
(35%) of the 99 subjects: in 34 (85%) of 40 severely
obese subjects and in 1(2%) of 59 non-obese subjects.
The incidence of high grade fatty liver was also signifi-
cantly higher in the severely obese group than the non-
obese group (p < 0.05). The incidence of fatty liver and
high grade fatty liver was not different between the dia-
betes and non-diabetes groups. Twenty four cases
(57.5%) of 40 severely obese patients were considered as
NASH. All NASH cases were associated with high grade
fatty liver.
Table 1 Relationship of fatty liver and high grade fatty liver with diabetes and severe obesity
Total (n = 99) Fatty liver (n = 63) High grade fatty liver (n = 35)
No (%) p-value No (%) p-value
Diabetics
No 50 30 (60) 0.447 16 (32) 0.481
Yes 49 33 (67) 19 (39)
Severe obesity
No 59 26 (44) <0.0009 1 (2) <0.0009
Yes 40 37 (93) 34 (85)
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cannalicular membrane of hepatocytes (Figure 1). The
CEACAM1 expression was lost mainly in the hepatocytes
with fatty change, particularly macrovesicular steatosis
(Figure 2). The relationship of a CEACAM1 expression
with diabetes, severe obesity, high grade fatty liver and
NASH was summarized in Table 2. A decreased CEA-
CAM1 expression was noted in 29 (29%) of 99 cases. A
decreased CEACAM-1 expression was associated with
high grade fatty change compared to absent or low grade
fatty change (p < 0.05). A decreased CEACAM1 expres-
sion was also associated with severe obesity with or with-
out diabetes rather than being associated with non-obesity
with or without diabetes (p < 0.05). The incidence of a
decreased CEACAM1 expression was significantly higher
in severely obese patients with NASH than severely obese
patients without NASH (p < 0.05). The incidence of CEA-
CAM1 expression was not different between the diabetic
and non-diabetic groups. A decreased CEACAM1 expres-
sion was noted in following descending order, severely
obese diabetics, severely obese non-diabetics, non-obese
diabetics and non-obese non-diabetics (p < 0.05) (Table
3). The relationship of high grade fatty liver, NASH and
CEACAM1 expression with severely obese patients that
were grouped into diabetics, non-diabetics with abnormal
glucose test and non-diabetics with normal glucose test,
was summarized in Table 4. There were no statistically
significant differences in high grade fatty liver, NASH and
a decreased CEACAM1 expression between 3 groups of
severely obese patients.
Discussion
Type 2 diabetes is caused by a combination of impaired
insulin secretion and insulin resistance, but their relative
contribution to the development of hyperglycemia may
differ due to the heterogeneity of this disease [2]. In
response to physiologic stimuli, insulin is secreted from
the pancreatic b-cells into the portal circulation in a pul-
satile manner [17]. Through its first passage, approxi-
mately 50% of the secreted insulin is cleared in the liver
[18,19]. Insulin clearance in liver is a critical regulator of
insulin’s action [19,20]. Impaired insulin clearance can be
the primary cause of insulin resistance by causing down-
regulation of insulin receptors and hepatic lipogenesis
[14,19]. CEACAM1 plays an important role in insulin
clearance by receptor-mediated insulin endocytosis and
degradation in the liver [12,18]. Abnormalities of insulin
clearance are present in various pathological conditions
including type 2 diabetes and severe obesity [19].
Obesity is intimately associated with the development of
insulin resistance and type 2 diabetes [21-23]. In obese
individuals, the adipose tissue releases increased amounts
of non-esterified fatty acids, glycerol, hormones, pro-
inflammatory cytokines and other factors that are involved
in the development of insulin resistance [24-28]. When
insulin resistance is accompanied by dysfunction of pan-
creatic islet beta-cells, this results in the development of
diabetes [1,25]. The homeostasis model assessment for
insulin resistance (HOMA-R) is strongly related to the
waist circumference and BMI [29]. In the present study,
40% of the severely obese non-diabetic group had abnor-
mal oral glucose tolerance testing, and this reflect the pre-
sence of insulin resistance, and the remainder of the
severely obese group might also be associated with some
degree of insulin resistance because they had extremely
high BMI. So, the higher incidence of a decreased CEA-
CAM1 expression in severely obese non-diabetic group
than non-obese non-diabetic group reflects the possible
association between a decreased hepatic CEACAM expres-
sion and insulin resistance.
AB
Figure 1 The liver tissue is not associated with fatty change (A) and it shows positive staining for CEACAM1 alongside the
cannalicular membrane of the hepatocytes on immunohistochemistry (B).
Lee Diagnostic Pathology 2011, 6:40
http://www.diagnosticpathology.org/content/6/1/40
Page 3 of 6B A
Figure 2 The liver tissue is associated with severe fatty change (A) and it shows a distinct loss of CEACAM1 expression
immunohistochemically (B).
Table 2 Relationship of a decreased CEACAM1 expression with diabetes, severe obesity, high grade fatty liver and
non-alcoholic steatohepatitis
Total (n = 99) Decreased CEACAM1 expression (n = 29) (%) p-value
Diabetics
No 50 13 (26) 0.467
Yes 49 16 (33)
Severe obesity
No 59 1 (2) <0.0009
Yes 40 28 (70)
High grade fatty liver
No 64 0 (0) <0.0009
Yes 35 29 (83)
Non-alcoholic steatohepatitis* <0.0009
No 17 6 (35)
Yes 23 22 (96)
* Only 40 severely obese patients was examined for non-alcoholic steatohepatitis
Table 3 Relationship of high grade fatty liver and a decreased CEACAM1 expression with diabetics and non-diabetics
with or without severe obesity
Total (n = 99) High grade fatty liver (n = 35) Decreased CEACAM1 expression (n = 29)
No (%) p-value No (%) p-value
Severely obese diabetics 20 18 (90) <0.0009 15 (75) <0.0009
Severely obese non-diabetics 20 16 (80) 13 (65)
Non-obese diabetics 29 1 (3) 1 (3)
Non-obese non-diabetics 30 0 (0) 0 (0)
Table 4 High grade fatty liver, non-alcoholic steatohepatitis and a decreased CEACAM1 expression between 3 groups
of severely obese patients
Total (n = 40) High grade fatty liver (n
= 34)
Non-alcoholic steatohepatitis
(n = 23)
Decreased CEACAM1 expression
(n = 28)
No (%) p-value No (%) p-value No (%) p-value
Diabetics 20 18 (90) 0.083 13 (65) 0.412 15 (75) 0.574
Non-diabetics 8 8 (100) 5 (65) 6 (75)
with abnormal GTT
Non-diabetics with normal GTT 12 8 (67) 5 (41) 7 (58)
GTT: glucose tolerance test
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not different between the diabetics and non-diabetics in
the obese or non-obese groups. This result does not sup-
port the previous experimental animal model studies
[11,12]. It could have been caused by the limitation of
immunohistochemical study for conducting a quantita-
tive analysis. In obese group, the CEACAM1 expression
was not different between the diabetics and non-diabetics
with normal or abnormal glucose tolerance test, yet both
the obese diabetic and obese non-diabetic groups had
significantly decreased CEACAM1 expression rather
than non-obese group. This data suggest the following
hypothesis: because a decreased CEACAM1 expression
in the obese group is an early event that occurs at the
time of insulin resistance and it consistently persists with
overt diabetes on a same level, the difference of the CEA-
CAM1 expression between the obese diabetic and obese
non-diabetic groups cannot be observed. To clarify this,
further study using more a precise analytic method such
as Western or Northern blotting is necessary.
Najjar et al [12,30] reported that transgenic mice, phos-
phorylation-defective S503A-CEACAM1 mutant devel-
oped visceral obesity with an increased amount of plasma
free fatty acid and plasma and hepatic triglyceride content.
Subsequently, they reported that CEACAM1 null mice
showed the loss of insulin’s ability to acutely decrease the
hepatic fatty acid synthase (FAS) activity [30]. Generally,
insulin is viewed as a positive regulator of fatty acid synth-
esis by increasing the transcription of FAS mRNA [30].
However, insulin acutely reduces the hepatic FAS activity
by inducing phosphorylation of CEACAM1 and its inter-
action with FAS [30]. This mechanism acts to reduce the
hepatic lipogenesis incurred by insulin pulses during
refeeding [30]. In the present study, the CEACAM1
expression in the liver was significantly decreased in the
severely obese subjects, high grade fatty livers and NASH.
Interestingly, the hepatocytes with fatty change, and parti-
cularly those with macrovesicular steatosis, revealed the
loss of a CEACAM1 expression. This data is in agreement
with Najjar et al [11,12,14]’s data from experimental
animal models.
Liver steatosis is frequently found in type 2 diabetics
and in severely obese patients [21,23,31]. One study
reported that steatosis was found in 86% of the severely
obese subjects who undergo bariatric surgery [32]. In the
severely obese group of the present study, 93% of these
subjects had an associated fatty liver. Moreover, the
degree of fatty liver was mainly high grade. The incidence
and grade of fatty liver were not different between the
diabetic and non-diabetic groups among the obese
groups. This data suggests the hypothesis that a fatty
liver is more likely related to the degree of obesity rather
than to the blood glucose level in the pathogenesis of
fatty liver associated with obese people with or without
diabetes.
In conclusion, the CEACAM1 expression was
decreased in the liver of severely obese patients with or
without diabetes. This study supports that a decreased
CEACAM1 expression in liver is related to obesity and
a fatty liver. However, the relation between decreased
CEACAM1 expression and diabetes was not supported
in this study. Larger series with more complex studies
are needed to further clarify this.
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